In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China

Li, Shuguang; Guo, Yinfeng; Zhao, Chunjiang; Chen, Hongbin; Hu, Bijie; Chu, Yunzhuo; Zhang, Zhijie; Hu, Yunjian; Li, Yong; Du, Yijun; Gui, Qiaodi; Ji, Ping; Zeng, Jing; Cao, Bin; Fu, Qihua; Zhang, Rong; Wang, Zhongxin; Zhuo, Chao; Feng, Xin; Jia, Wei; Jin, Yan; Xu, Xuesong; Liao, Kang; Ni, Yizhao; Yu, Yunsong; Xu, Xiuli; Hu, Zhidong; Lei, Jin’e; Yang, Qing; Wang, Hui

doi:10.1099/jmm.0.000347

Cited by 23 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, both antibiotics showed potent in vitro activity against MRSA strains from different infection types and different patients (with different morbidity and age), as was shown in previous studies (Múnera et al, 2017;Lee et al, 2015;Li et al, 2016). Moreover, both antibiotics were effective against different spa types and pvl presence did not affect susceptibility.…”

Section: Discussionsupporting

confidence: 80%

“…Most of the studies that had evaluated Tedizolid or Dalbavancin activity did not compare MRSA isolates from different clinical samples. Li et al (2016) presented the Tedizolid MIC values of MRSA strains from hospital-acquired pneumonia (HAP), blood and SSSI samples, did not find any significant difference between these two groups. However, no statistical test was applied for this question.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source

Azrad

Baum

Rokney

et al. 2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Objective: We tested the in vitro susceptibility to Tedizolid and Dalbavancin of Methicillin-resistant Staphylococcus aureus strains recovered from blood and wound cultures, and compared our results with studies conducted in the last four years. We examined whether the spa types affect the susceptibility of the different strains. Methods: We analyzed 275 Methicillin-resistant S. aureus strains recovered from 128 blood and 147 wound samples. For each strain, we performed minimum inhibitory concentration for Tedizolid and Dalbavancin and spa typing. We also performed a non-systematic review of the worldwide literature from the last four years concerning the in vitro activity of Tedizolid and Dalbavancin using the PubMed database; results were restricted by Results: We found one Dalbavancin-resistant isolate (0.36%) and no resistance to Tedizolid. The minimum inhibitory concentration values were dependent in the strain source (wound vs. blood) for both antibiotics. For Dalbavancin, there was also dependence on the spa type. Conclusion: This study indicates Tedizolid and Dalbavancin have potent in vitro activity against the prevalent S. aureus clones in Israel. Further studies should be performed in order to uncover the factors contributing to reduced susceptibility of S. aureus strains to new drugs.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 93%

In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source

Azrad

Baum

Rokney

et al. 2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…The clinical specimens were processed based on the recommended microbiology procedures as we previous described [9][10][11][12]. Species identi cation when available was con rmed on colony morphology, conventional biochemical reactions and/or use of an automated system (bioMerieux, Marcy l'Etoile, France).…”

Section: Isolate Identi Cationmentioning

confidence: 99%

Microbial Predominance and Antimicrobial Resistance in a Tertiary Hospital: A Six-year Retrospective study from Outpatients and Patients Visiting the Emergency Department

Wang

Gao

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: To assessing the characteristics of of microbial species and the antimicrobial resistance in a Tertiary Hospital with 49 outpatient clinics and emergency department in Northwestern China, of six years. Methods: A retrospective study was conducted using HIS database of a tertiary hospital between the full-year period of 2013 and 2018. Antimicrobial susceptibility tests were conducted by automated systems and/or the Kary-Bauer disc diffusion method. Data were analyzed using the WHONET 5.6 software. The Cochran–Armitage test was used to study the trends over the period. Results: A total of 19,028 specimens were submitted for the laboratory tests of microbiology. Among 49 units, only Emergency Department and Kidney Transplantation Clinic with the number of submission showed a significant increase annually (P<0.001). A total of 3,849 non-repetitive isolates were identified, covering more than 200 species, of which gram-positive cocci accounted for 46.4% and gram-negative bacilli 45.3%. The methicillin-resistant rates of S. aureus and S. epidermidis were 25.1% and 74.6%, respectively. The isolates of 60.9% of E. coli and 33.5% of K. pneumonia contained extended spectrum β lactamases. Moreover, there were no Staphylococci and Enterococci resistant to linezolid, vancomycin and tigecycline. In addition, the percentages of E. coli, K. pneumonia and P. aeruginosa isolates resistant to carbapenems were low (0.0%, 1.1% and 18.7%, respectively). Conclusion: Vancomycin, linezolid and tigecycline are among the most effective treatment for outpatients with gram-positive infection. Carbapenems are among the most effective for gram-negative infection. There is no significant annual increase of common multidrug resistances.

show abstract

“…11,[12][13][14][15][16][17] Of note, a greater intracellular accumulation 18 and at least 4-times greater in vitro potency of tedizolid compared with linezolid have been demonstrated in previous studies. 19,20 Furthermore, tedizolid has been described with a more favourable pharmacokinetic profile than linezolid in both Caucasian 21,22 and Asian healthy subjects. 23,24 Tedizolid has recently been approved in the USA, Canada, Europe, Japan and other countries for the treatment of acute bacterial skin and skin structure infections (ABSSSIs); its efficacy and safety have also been demonstrated in Chinese patients with ABSSSI.…”

Section: Introductionmentioning

confidence: 99%

Comparative in vitro potency and kill curve activity of tedizolid and linezolid against Gram-positive bacteria isolated from Chinese hospitalized patients in 2013–2016

Wang

Xue

et al. 2019

Journal of Chemotherapy

View full text Add to dashboard Cite

We compared the kill-curve activity of tedizolid and linezolid at clinically relevant (total or free plasma, lung) concentrations against methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP) isolated from Chinese patients. Tedizolid had greater in vitro potency than linezolid against staphylococci, streptococci and enterococci species (tedizolid minimum inhibitory concentration (MIC) range: 0.016-0.5 mg/mL; linezolid MIC range: 0.25-2 mg/mL). In kill-curve experiments, growth of MRSA was inhibited at tedizolid concentration of 0.6 mg/mL (i.e. 4.8 Â MIC; MIC ¼ 0.125 mg/mL) and linezolid concentration of 2 mg/mL (2Â MIC; MIC ¼ 1 mg/mL). Against PRSP, tedizolid at a concentration of 0.25 mg/mL (representing its MIC) was bacteriostatic, but exerted a bactericidal effect at higher concentrations. Results were similar for linezolid, however, even at 21 mg/mL, a small proportion of organisms survived beyond 24 h. The results demonstrated the potency of tedizolid against clinical strains of Gram-positive pathogens supporting its use as a suitable alternative to linezolid in Chinese patients.

show abstract

In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China

Cited by 23 publications

References 31 publications

In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source

In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source

Microbial Predominance and Antimicrobial Resistance in a Tertiary Hospital: A Six-year Retrospective study from Outpatients and Patients Visiting the Emergency Department

Comparative in vitro potency and kill curve activity of tedizolid and linezolid against Gram-positive bacteria isolated from Chinese hospitalized patients in 2013–2016

Contact Info

Product

Resources

About